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Abstract 
Background: Activation of hypnozoites of vivax malaria causes multiple clinical relapses, which contribute to the 
Plasmodium vivax burden and continuing transmission. Artemisinin-based combination therapy (ACT) is effective 
against blood-stage P. vivax but requires co-administration with primaquine to achieve radical cure. The therapeutic 
efficacy of primaquine depends on the generation of a therapeutically active metabolite via cytochrome P450 2D6 
(CYP2D6). Impaired CYP2D6 metabolism has been associated with primaquine treatment failure. This study inves-
tigated the association between impaired CYP2D6 genotypes, drug-exposure to the long-acting ACT component 
(schizonticidal drugs) and tolerance and efficacy.
Methods: Adult patients with acute vivax malaria were enrolled in a recently completed trial and treated with artesu-
nate–mefloquine, chloroquine or artemether–lumefantrine. All received concomitant primaquine (0.5 mg/kg/day for 
7–9 days). The association between efficacy and safety and drug exposure was explored using area-under-the-curve 
(AUC) and half-life  (t1/2) estimates obtained by non-compartmental analysis of the long half-life drugs. Parasite recur-
rences by day 63 were categorized as related relapses or re-infections/unrelated hypnozoite activation by genotyping 
three microsatellite loci and two polymorphic loci of merozoite surface antigen-1. The CYP2D6 genotype was identi-
fied with Taqman assays by real-time PCR to 9 polymorphisms (8 SNPs and one deletion). Impaired CYP2D6 activity 
was inferred using the Activity Score System.
Results: Most recurrences in the ASMQ (67%), CQ (80%) and AL (85%) groups were considered related relapses. Eight 
of nine (88.9%) of the patients with impaired CYP2D6 activity relapsed with related parasite compared to 18/25 (72%) 
with normal activity (RR = 1.23, 0.88; 1.72, p = 0.40). There were no associations between the measured PK parameters 
and recurrence. Patients with longer chloroquine half-lives had more pruritus (RR = 1.09, 1.03; 1.14, p = 0.001). Higher 
CQ AUCs were associated with reduced falls in haemoglobin by day 14 (Coef − 0.02, − 0.005; − 0.03, p = 0.01). All 
regimens were well tolerated.
Conclusion: Genotyping of P. vivax showed that activation of related (homologous) hypnozoites was the most 
frequent cause of recurrence. The high proportion of the impaired CYP2D6 activity among patients with recurrent 
infections suggests that slow primaquine metabolism might influence related relapse rates in Brazil among patients 
receiving primaquine for radical cure, although confirmatory studies are needed. There was no association between 
drug exposure of the long-acting ACT component (schizonticidal drugs) and risk of related relapse. ACT was well 
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Background
The biological features of vivax malaria provide major 
challenges for pre-elimination and elimination pro-
grammes in areas co-endemic for Plasmodium falcipa-
rum and Plasmodium vivax [1]. These features include 
the early appearance of gametocytes, a high proportion 
of asymptomatic or chronic carriers [2] and the parasite 
latent form hypnozoites that produce relapses. Relapses 
make a major contribution to the global P. vivax burden 
[3]. It was estimated that relapses constituted 76–90% 
and 79% of total infections in Papua New Guinea and 
Thailand, respectively [4]. To eliminate this reservoir of 
latent infections, simple effective radical treatment of 
vivax using 8-aminoquinolines, such as primaquine or 
the recently approved analogue tafenoquine, is required.
In most countries with endemic P. vivax, the preferred 
first-line radical treatment for P. vivax remains chloro-
quine, combined with 7- to 14-day primaquine regimens, 
and this has barely changed since the 1950s [5]. Chloro-
quine is no longer recommended for the case manage-
ment of falciparum malaria due to the spread of parasite 
resistance [6], resulting in the use of different treatment 
regimens for P. vivax and P. falciparum in areas where 
these species are co-endemic. This is programmatically 
complicated. The use of a single regimen to treat all spe-
cies of malaria would simplify malaria treatment guide-
lines [7]. Artemisinin-based combination therapy (ACT) 
is emerging as the best option in this context, particularly 
in settings where there are concerns about chloroquine-
resistant P. vivax [8]. ACT is effective against the blood 
stage of P. vivax [9], but must be co-administered with 
primaquine to eliminate P. vivax hypnozoites [8, 10]. 
Short-course primaquine regimens are preferable as they 
have been proven to have an efficacy not inferior to the 
standard 14 days’ regimens [11–14]. However, there is a 
relative lack of data on the safety, pharmacodynamics and 
pharmacokinetics of ACT when provided in combination 
with daily primaquine regimens for the radical cure of P. 
vivax [15]. Safety is a major concern when deploying new 
treatments, but there are also concerns that primaquine/
ACT drug interactions may reduce the overall regimen 
efficacy by inhibiting CYP2D6 or reducing synergistic 
effect of the current regimen. There are uncertainties 
about the best partner ACT, as drugs with a longer half-
life may prevent early relapses.
Characterization of parasites and patients’ drug 
metabolism is needed to ascertain the pharmacodynam-
ics, pharmacokinetics and therapeutic success of these 
regimens. The main malaria clinical trials outcomes 
are parasitological clearance and recurrence rate [16]. 
Vivax recurrence includes: (i) recrudescence of parasites 
that have been previously cleared and microscopically 
undetectable; (ii) re-infection from another mosquito 
bite; and, (iii) relapses, i.e., activation of hypnozoites, 
genetically related (homologous) or unrelated (heterolo-
gous). The primaquine metabolite that is active against 
human hypnozoite is unknown [17], but the metabo-
lism of primaquine to its active metabolite is depend-
ent on the cytochrome P450 enzyme CYP2D6 [17–19]. 
Low CYP2D6 activity results in slow metabolism of pri-
maquine to the active metabolite. CYP2D6 activity may 
be a proxy of primaquine’s active metabolite exposure 
and a risk factor for relapse among primaquine recipi-
ents [20–22]. Similarly, the cytochrome P450 enzymes 
CYP2C8 was investigated as it is known to participate in 
the metabolism of chloroquine [23].
A previous randomized clinical trial in Brazil of the 
treatment of uncomplicated vivax malaria compared the 
safety and efficacy of the fixed-dose ACT artemether–
lumefantrine and artesunate–mefloquine against the 
standard treatment with chloroquine, all three in combi-
nation with short-course primaquine (0.5 mg/kg/day for 
7–9 days) [24]. This current study investigated the phar-
macokinetics of the long-acting ACT component (schiz-
onticidal drugs) with concomitant primaquine upon the 
safety and efficacy of these three treatment regimens and 
the influence of genetic variability of parasite and host, 
including the frequency of mutations in CYP2D6 gene 
over relapse rate.
Methods
Overview study design
The patients included in the current analysis were 
enrolled in a larger clinical trial previously published and 
designed in accordance with WHO guidelines [16]. The 
trial was designed to evaluate the safety and efficacy of 
the schizonticidal drugs with concomitant use of pri-
maquine for vivax cure. The details of the trial design 
and methods have been reported elsewhere [24]; in brief, 
patients were eligible if they had acute uncomplicated 
tolerated. These results provide further re-assurance about the safety and efficacy of ACT when combined with short 
course primaquine to treat uncomplicated malaria vivax in Brazil.
Trial registration RBR-79s56s (http://www.ensai oscli nicos .gov.br/rg/RBR-79s56 s/)
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malaria due to P. vivax mono-infection confirmed by 
microscopy, with fever or a history of fever in the previ-
ous 48 h, were aged 18 to 70 years old, weighed between 
50 and 90  kg, and had parasite densities > 250/μL and 
haemoglobin levels > 7.0  g/dL. G6DP deficiency was not 
an exclusion criterion. They were randomly allocated 
to three treatment groups: (a) artesunate–mefloquine 
(100 + 200 mg QD for 3 days) (ASMQ); (b) chloroquine 
(CQ) (600  mg on day 1, and 450  mg on days 2 and 3); 
and, (c) artemether–lumefantrine (20 + 120  mg BID for 
3 days) (AL). All three arms received the same concomi-
tant primaquine regimen (7–9 days: 0.5 mg/kg/day).
Patients were assessed on the day of enrolment and 
days 1, 2, 3, 7, 14, 21, 28, 42, and 63. The main endpoints 
were either treatment failure or adequate clinical and 
parasitological response. Blood samples were collected 
for parasite counts at every scheduled visit, on any day 
of treatment failure and for drug levels on days 0, 3, 7, 
14, 21, 28, 42, and 63. Samples (100 μL) were transferred 
to Whatman (USA) ET 31 CHR E 3MM filter papers for 
later pharmacokinetic analysis and parasite genotyping 
[25].
Parasitological densities were estimated using Giemsa-
stained blood slides at a magnification of 1000× using 
WHO-recommended methods [16]. Adverse events 
(AE) were assessed at each follow-up visit, and patients 
were encouraged to return to the clinic if they were ill in 
between scheduled visits. All AEs, including laboratory 
abnormalities, were categorized by body system.
Pharmacokinetics/pharmacodynamics
Whole blood concentrations of mefloquine (MQ), chlo-
roquine (CQ) and lumefantrine (LMF) were measured 
using a validated HPLC-MS/MS method in accordance 
with Brazilian [26] and international regulatory require-
ments for bio-analytical methods [27]. The pharma-
cokinetics assays were conducted at the Equivalence 
and Pharmacokinetics Service (SEFAR)/Oswaldo Cruz 
Foundation, which is accredited by the Brazilian regula-
tory agency, Agência Nacional de Vigilância Sanitária 
(ANVISA). Non-compartmental analysis was performed 
for CQ, LMF and MQ using the  Pmetrics® [28] package 
to estimate two main parameters; the overall area under 
the curve (AUC)(3–63  days) and the terminal elimination 
half-life  (t1/2). The terminal elimination half-life was only 
calculated for subjects with five or more available sam-
ples. These two parameters were used as proxy indicators 
for overall drug exposure for correlation analyses with 
drug efficacy and safety profiles.
The correlation between drug exposure and treatment 
failure was evaluated using the Mann–Whitney test. The 
effect of pharmacokinetic parameters on the frequency 
of AEs likely or probably related to the test drug was 
expressed as the relative risks (RR) obtained from ran-
dom effects generalized estimation equation (GEE) log-
binomial regression models. Linear regression was used 
to test the effects of PK parameters on the fall in haemo-
globin (Hb) concentrations by day 14 relative to enrol-
ment values [29]. The effects of these pharmacokinetic 
parameters on treatment failure (both early and later 
failures) were evaluated as odds ratios (OR) from bino-
mial logit link regression models, using generalized linear 
models (GLM). Time to failure was tested using standard 
Cox regression. The proportion of clonal variability at 
recurrence was compared between treatment arms using 
Fisher’s exact test. Two-sided p-values of < 0.05 were con-
sidered statistically significant.
DNA extraction and genotyping of parasites microsatellites 
and polymorphic blocks of MSP‑1 and patients’ CYP2D6 
and CYP2C8
DNA was extracted from dried blood using QIAamp 
DNA blood mini kit (Qiagen, Hilden, Germany) follow-
ing the instructions of the manufacturer. Three micros-
atellite loci (MS2, MS6, MS7) and two polymorphic loci 
(blocks 2 and 10) of Merozoite surface antigen 1 (MSP-1) 
were amplified using specific primers and conditions as 
previously described [30, 31]. The exact length and rela-
tive abundance (fluorescence levels) of each PCR product 
were determined in the DNA automatic sequencer (ABI 
3730, Applied Biosystems, Thermo Fischer Scientific, 
Waltham, MA, USA) with fluorescein-labelled forward 
primers and an internal size standard (GeneScan 500 
LIZ, Applied Biosystems). The predominant allele for 
each locus was identified as the highest peak of fluores-
cence in the electropherogram using GeneMapper 4.1 
software (Applied Biosystems). The multiplicity of para-
site variants was estimated measuring extra peaks in the 
electropherogram with fluorescence above the cut-off 
(150 arbitrary fluorescence units) and at least one-third 
the high of the main peak. Parasite recurrences within 
63  days were categorized as ‘related’, including totally 
identical (homologues) if all five polymorphic loci (MS2; 
MS6; MS7; MSP1B2; MSP1B10) were identical and ‘simi-
lar’ if 80% of their alleles were identical; and otherwise 
as unrelated (heterologous) (Additional file  1). Number 
of alleles and heterozigosity expected were calculated in 
Arlequim software v. 3.5.2.2 (http://cmpg.unibe .ch/softw 
are/arleq uin35 /).
The cytochrome P450 enzymes CYP2D6 [17, 19] and 
CYP2C8 [23] are known to participate in the metabolism 
of the primaquine and chloroquine, respectively. Two 
SNPs (G416A[rs11572080] and A805T [rs11572103]) 
were genotyped in the CYP2C8 gene. In the CYP2D6 
gene eight SNPs were genotyped; (G-1584C [rs1080985], 
C100T [rs1065852], C1023T [rs28371706], G1846A 
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[rs3892097], C2850T [rs16947], G2988A [rs28371725], 
G3183A [rs59421388] and G4180C [rs1135840]) and one 
deletion (2615-2617delAAG [rs5030656]) were geno-
typed. The copy number was also determined. All SNPs 
genotyping were performed by real-time PCR using 
specific hydrolysis probe [22] in ViiA 7 Real-time PCR 
system (Applied Biosystems). Haplotypes and CYP2D6 
star alleles were inferred using the Phase software (ver-
sion 2.1). CYP2D6 gene copy number was determined 
with Hs00010001_cn assay (Applied Biosystem) in Real-
time PCR [20]. Each allele got one value that was used to 
calculate the CYP2D6 activity score (AS). Patient were 
categorized based on their AS score into normal metabo-
lizer fast (gNM-F) (AS = 1.5 or 2.0), normal metabolizer 
slow (gNM-S) (AS = 1), intermediate metabolizer (gIM) 
(AS = 0.5), poor metabolizer (gPM) (AS = 0), and ultra 
metabolizer (gUM) (more than 2 copies of the normal 
allele) (AS ≥ 2.0). Impaired CYP2D6 activity was defined 
as AS scores less than 1.5 (Additional file 2).
Results
Population
The study is based on a sub-set of samples from the 
original trial. Only 2/3 of samples (1400 samples of 175 
patients) were evaluated in pharmacokinetics/pharma-
codynamics analysis due to logistical issues, however the 
baseline characteristics of this sub-set were similar across 
the three arms (Table  1). Characterization of parasites 
and drug metabolism was conducted in all 35 patients 
with parasite recurrence within 63 days.
Characterization of parasites and drug metabolism 
in the population with treatment failure
The frequency of related (homologous and similar) and 
unrelated (heterologous) parasites among 35 patients 
with parasite recurrence within 63 days by study arm is 
shown in Table 2. Overall, 67, 80 and 85% of the recur-
rent malaria in the ASMQ, CQ and AL groups, respec-
tively, were considered related relapses. Among the 
recurrences the pooled percentage of related relapses 
across the three arms was 77.1%.
Genetic analysis of the parasite populations com-
paring all recurrences also demonstrated that 77.1% 
(27/35) of patients presented with a single clonal infec-
tion at the initial infection and at the recurrence. The 
number of parasite variants between initial infection 
and recurrence remained the same in 23 (65.7%) of the 
35 patients with recurrent infections and increased in 
10 (28.5%) and decreased in 2 (5.7%). There was no dif-
ference in multiplicity of parasite clones at recurrence 
between treatment arms (p = 0.51).
Cyp2d6
Eight of 9 (88.9%) patients classified to have reduced 
enzymatic activity for primaquine metabolism based 
on their CYP2D6 genotypes relapsed with related para-
sites (RR = 1.23 95% CI (0.88–1.72) p = 0.40) (Table 3). 
Eighteen out of 25 (72%) normal metabolisers had 
related relapses.
Table 1 Baseline characteristics of the study population
Data represent n (%) and means and (SD)
a Parasitaemia was expressed by geometric mean and [min–max]
ASMQ CQ AL
N of patients 60 58 57
Male n (%) 35 (58) 46 (79) 39 (68)
Weight in kg 70 (11) 73 (10) 73 (10)
Haemoglobin in g/dL 13.4 (1.8) 14.0 (3) 13.6 (2)
Parasitaemia/μLa 2145.56 [258–13,335] 2155.78 [285–17,685] 2444.71 [270–19,815]
Age in years 39.0 (11) 42.1 (10.5) 38.7 (11)
Table 2 Clinical outcomes aggregated by drug treatment (%)
Clinical outcome (%) PCR results ASMQ CQ AL Overall
Related relapse Homologous 6 66.7% 6 80.0% 8 84.6% 20 77.1%
Similar 2 2 3 7
Reinfections or unrelated 
hypnozoites’ activation
Heterologous 4 33.3% 2 20.0% 2 15.4% 8 22.9%
Overall 12 10 13 35
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Cyp2c8
The frequency of two polymorphisms in CYP2C8 gene 
in the population who failed is presented in Table  4. 
Out of the 10 patients in the CQ arm with parasite 
recurrence, one had the SNP G416A genotype indica-
tive of reduced enzyme activity of CYP2C8. The AUC 
and half-life for chloroquine of this patient were 
91.9  µg/mL  h and 11.32  days, respectively, compared 
with 102.3  µg/mL  h and 19.3  days in the 9 CYP2C8 
non-mutated genotypes in the CQ arm. These results 
for the patient with the mutated genotype fall within 
the 95% CI for the overall population (Table 5).
Pharmacokinetics/pharmacodynamics
AUC 0–63  day values were calculated for each patient in 
each arm; the terminal elimination half-life  (t1/2) could 
only be calculated for those receiving CQ or MQ. Fig-
ure  1 shows the terminal PK profile generated for MQ, 
CQ and LMF.
Drug exposure (defined by AUC 3–63  day or elimination 
half-life) under the therapeutic threshold could poten-
tially explain the relapses and recrudescence, but not 
re-infections. The relationship of drug exposure (defined 
by AUC 3–63  day or elimination half-life) to recurrence 
was investigated by comparing the PK parameters in 
the cured population with those with confirmed related 
relapse (homologous + similar). There were no statisti-
cally significant differences in AUC 3–63 day or elimination 
half-life for MQ, CQ or LMF between patients without 
recurrent infections by day 63 and those with relapses 
in univariate (Table 5). Weight and gender were also not 
associated with parasite recurrence by day 63 (Additional 
file 3), parasite clearance by day 3 (Additional file 4), or 
time to failure (Additional file 5).
Higher drug exposures could be associated with a 
higher frequency of AEs. The influence of AUC, half-life 
and weight on the frequency of AEs likely and probably 
related to the treatment per body systems (n ≥ 30) are 
presented in Additional file 6. The relative risk of having 
pruritus increased as the half-life of CQ increased (RR 
1.09, 95% CI 1.03–1.14, p = 0.001). Conversely, the influ-
ence of drug exposure on the Hb drop (defined as Hb at 
Table 3 Inferred phenotype of CYP2D6 based on genotyping by treatment arm (%)
AS activity score, gNM-F normal-fast metabolizer, gUM ultrarapid metabolizer, gNM-S normal-slow metabolizer, gIM intermediate metabolizer, gPM poor metabolizer
a CYP2D6 phenotype of two patients (ID 33 and 231) could not be defined
CYP2D6 metabolism AS Phenotype ASMQ CQ ALa
Normal 1.5 or 2 gNM-F 5 50.0% 9 90.0% 9 81.8%
≥ 2 gUM 1 0 0
Impaired 1 gNM-S 5 50.0% 0 10.0% 2 18.2%
0.5 gIM 0 1 0
0 gPM 1 0 0
Table 4 Inferred phenotype of  CYP2C8 based 
on genotyping by drug treatment group
a All mutants are heterozygotes
CYP2C8 (SNP) Genotype MQ CQ LMF
G416A Normal 7 9 13
Mutanta 5 1 0
A805T Normal 12 10 13
Mutant 0 0 0
Table 5 Median of  pharmacokinetic parameters for  mefloquine, chloroquine and  lumefantrine in  patients 
with homologous parasites by treatment outcome
Overall values are median with 25–75 percentiles in square brackets and N = 59
NA non-applicable
Mefloquine Chloroquine Lumefantrine
Cure Relapse p‑value Cure Relapse p‑value Cure Relapse p‑value
N of patients 53 6 – 52 7 – 52 7 –
AUC (0–63 day) (µg/mL h)
 Per outcome 338.6 302.0 0.67 105.9 95.8 1.0 7.3 3.73 0.96
 Overall 338.6 [256.0–408.0] – 103.8 [83.0–126.3] – 6.7 [2.7–12.0] –
Half-life (days)
 Per outcome 17.7 25.6 0.58 18.5 19.3 0.42 NA NA –
 Overall 17.8 [15.0–24.8] – 18.7 [15.4–27.8] – NA –
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day 14 − Hb at baseline/Hb at baseline) shown that the 
higher the AUC of CQ the lower the reduction in the Hb 
decline (Coef −  0.02, 95% CI −  0.03; −  0.00, p = 0.01) 
(Additional file 7). Please number in sequence i.e. first 6 
then 7).
Discussion
This study showed by genotyping polymorphic loci of P. 
vivax that relapse due to related parasites was the most 
frequent cause of recurrence by day 63 in all three treat-
ment arms of the previous trial [32], where 13–16% of 
infections recurred by day 63. The current study also 
showed that the treatment failure rate in patients with 
reduced inferred CYP2D6 activity (26%) was higher 
than in the general population (≅ 11%) [33]. Moreo-
ver, 8 out of 9 recurrences among patients with low 
CYP2D6 activity were related relapses compared to 18 
out of 25 with inferred normal CYP2D6 activity. Low 
CYP2D6 activity and presumptive low exposure to the 
active metabolite of primaquine or disruption of the PQ-
enzyme interactions might influence related relapse rates 
in Brazil, although further studies are need to elucidate 
this effect. Likewise, the impaired activity of CYP2C8 
may result in a lower exposure to desethylchloroquine, 
the chloroquine active metabolite. The PK parameters 
and clinical outcomes of the single patient with impaired 
CYP2C8 in CQ arm did not differ from the overall 
population.
Other causes of low exposure to primaquine are also 
potential risk factors for relapses, such as low adherence 
or impaired bioavailability. Similarly, others factors which 
affect the success of anti-infective therapeutics may 
influence the responses to the radical treatment, such as 
Fig. 1 Pharmacokinetic profile of Mefloquine (MQ), Lumefantrine (LMF) and Chloroquine (CQ). Profiles were generated from 58 to 60 subjects for 
each drug. Data shows median with 95 confidence interval (CI). a Mefloquine concentration over the time, b lumefantrine concentration over the 
time and c chloroquine concentration over the time
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differences in the biology of the parasite, the immune sta-
tus of the patients and the density of latent hypnozoites 
[34].
This was the first time that some of the ACT com-
binations, namely ASMQ, were evaluated for the cure 
of P. vivax in clinical trial conditions, and thus in com-
bination with daily primaquine (0.5  mg/kg/day for 
7–9  days) regimens. The correlation between drug 
exposure to the long-acting components of the ACT 
and the risk of recurrence and AEs was also assessed. 
Potential interactions between primaquine and the 
ACT, and also the safety of these regimens, have not 
been extensively assessed [15]. Drug interactions such 
as lumefantrine inhibiting CYP2D6 [35] may reduce 
the overall regimen efficacy; on the other hand, drugs 
with a longer half-life may prevent early relapses. This 
study could not demonstrate a significant associations 
between the PK parameters of the long half-life drugs 
and the risk of recurrence, or the risk of relapse due to 
either homologous and heterologous relapses or time to 
recurrence (Additional files 3, 4, 5), although the num-
bers of relapses were small. Patients with longer chlo-
roquine elimination half-life estimates were more likely 
to report pruritus. Transient, mild to moderate pruri-
tus is a well-known adverse effect of chloroquine [36] 
and a threat to treatment adherence. A smaller drop in 
haemoglobin by day 14 was associated with higher CQ 
exposure (AUC), which may reflect better therapeu-
tic efficacy achieved with higher concentrations of CQ 
[37].
This study has several limitations. The blood sampling 
schedule was designed to evaluate the blood levels of the 
long half-life drugs; the pharmacokinetic data allowed 
the prediction of the drug exposures up to 63 days post-
treatment with up to 8 sample points available for each 
patient. It did not allow a proper modelling of primaquine 
levels and limited the calculation of the elimination half-
life of lumefantrine. The absence of desethylchloroquine 
blood levels measurement is another study limitation. 
A trial designed with 6  months follow-up would have 
been able to evaluate relapses with more accuracy, as 
the median time to vivax recurrence in Brazil is 71 days 
[13]. The characterization of parasites and drug metabo-
lism were conducted only in 35 patients with treatment 
failure limiting the comparisons. Genotyping vivax par-
asites to infer relapse frequencies also presents limita-
tions. Genotyping in vivax does not allow differentiation 
between new infections (reinfections) or activation of 
unrelated (heterologous) hypnozoites. In this study, only 
recurrences with homologous and similar parasites were 
considered relapses. However, relapses are often heter-
ologous activation of hypnozoites [31, 38]. The recrudes-
cence of sub-microscopic parasite population [39] is also 
a biologically plausible explanation for homologous para-
sites in two samples. Future use of more sensitive para-
site detection strategies, such as ultrasensitive PCR of all 
consecutive samples of the patients who failed could elu-
cidate these results.
Conclusion
The genotyping of polymorphic loci of P. vivax showed 
that relapse due to genetically related parasites was the 
most frequent cause of recurrence in all three treatment 
arms. The high proportion of CYP2D6 genetic polymor-
phisms among patients with recurrent infections suggests 
that impaired primaquine metabolism might influence 
the related relapse rates in Brazil among patients receiv-
ing primaquine for radical cure, further studies are 
needed to confirm this finding. The three ACT regimens 
were very effective, and there was no association between 
drug exposure levels of the long-acting components of 
the ACT and risk of relapse. The ACT was well tolerated 
overall. These results provided further reassurance about 
the safety of the combined use of ACT and short-course 
primaquine (0.5 mg/kg/day for 7–9 days) to treat uncom-
plicated malaria vivax in Brazil.
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Additional file 1. Genotyping of Plasmodium vivax polymorphic loci from 
patients during initial infection and recurrence. Size of PCR products in 
base pairs (bp). #Number of patient and day of sample collection: d0—
diagnosis and treatment, dX—the day of recurrence. *Allele similar to 
initial infection present in lower intensity. NA non-amplified. 
Additional file 2. Genotyping of CYP2C8 gene and CYP2D6 gene and 
predicted phenotype of CYP2D6 activity. a CYP2D6 haplotype inferred 
using Phase software. b Activity score and inferred phenotype of CYP2D6: 
AS = 1.5 or 2 − normal metabolizer fast (gNM-F); AS ≥ 2 − ultra metabo-
lizer (gUM) (more than 2 copies of the normal allele); AS = 1 − normal 
metabolizer slow (gNM-S); AS = 0.5 − intermediate metabolizer (gIM); 
AS = 0 − poor metabolizer (gPM), according to Gaedigk et al. [20]. c Sum 
of AS attributed to allele 1 and 2 of CYP2D6 gene. NP not performed. 
Additional file 3. Evaluation of pharmacokinetics’ parameters, gender and 
weight as predictors of failures per treatment drug (Generalized Linear 
Model, binomial logit link). 
Additional file 4. Evaluation of pharmacokinetics’ parameters and weight 
as predictors of D3 failures per treatment drug (Generalized Linear Model, 
binomial logit link). Only available to chloroquine, all males. ASMQ and AL 
100% presented clearance at D3. 
Additional file 5. Evaluation of pharmacokinetics’ parameters, gender 
and weight as predictors of time to failures per treatment drug (Cox 
regression). 
Additional file 6. Evaluation of pharmacokinetics’ parameters as predic-
tors of frequent (n ≥ 30) adverse event (possible and likely related to 
treatment) per system and drug using Generalized Estimation Equation 
log-binomial regression. *CQ AUC and weigh correlation is significant at 
the 0.01 level (2-tailed). Weight was excluded as a covariate. 
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Additional file 7. Evaluation of pharmacokinetics’ parameters and weight 
as predictors of the drop in haemoglobin* at day 14 using ordinary least 
squares. *Hb at day 14 − Hb at baseline/Hb at baseline. **CQ AUC and 
weigh correlation is significant at the 0.01 level (2-tailed). Weight was 
excluded as a covariate. NA non-applicable.
Abbreviations
ACT : artemisinin-based combination therapy; AE: adverse events; AL: fixed 
dose combination of 20 + 120 mg artemether and lumefantrine with con-
comitant use of primaquine; ANVISA: National Regulatory Agency; AS: CYP2D6 
activity score; ASMQ: fixed dose combination of 100 + 200 mg artesunate and 
mefloquine with concomitant use of primaquine; AUC : area-under-the-curve; 
CQ: chloroquine; CI: confidence interval; CQ: chloroquine with concomitant 
use of primaquine; G6PD: glucose-6-phosphate dehydrogenase; GEE: general-
ized estimation equation; GLM: generalized linear models; Hb: haemoglobin; 
HPLC-MS/MS: high performance liquid chromatography-tandem mass spec-
trometry; LMF: lumefantrine; MQ: mefloquine; OR: odds ratio; PCR: polymerase 
chain reaction; RR: relative risks; SD: standard deviations; SEFAR: Equivalence 
and Pharmacokinetics Service; t1/2: half-life; WHO: World Health Organization.
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